[1] Pape S, Snijders R, Gevers TJG, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group[J]. J Hepatol,2022,76:841-849. [2] Slooter CD, van den Brand FF, Lleo A, et al. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry[J]. Hepatology,2024,79:538-550. [3] Choi J, Choi GH, Lee D, et al. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country[J]. Liver Int,2019,39:985-994. [4] Hartl J, Ehlken H, Sebode M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol,2018,68:754-763. [5] Li Y, Xiao X, Miao Q, et al. Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis[J]. J Hepatol, 2022,77:1463-1464. [6] Couto CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis[J]. Hepatology,2014,59:592-600. [7] Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology,2020,72:671-722. [8] Li Y, Yan L, Wang R, et al. Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review[J]. Clin Rev Allergy Immunol,2022,62:292-300. [9] Toniutto P, Zorzi M, D'Alì L, et al. Baseline Predictors of the Long-Term Insufficient Biochemical Response in Patients with Autoimmune Hepatitis: A Single Center Experience[J]. J Clin Med,2023,12. [10] Pape S, Gevers TJG, Vrolijk JM, et al. Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months[J]. Clin Gastroenterol Hepatol,2020,18:1609-1617.e1604. [11] Zandanell S, Balcar L, Semmler G, et al. Genetic Variants Determine Treatment Response in Autoimmune Hepatitis[J]. J Pers Med,2023,13. [12] Diestelhorst J, Junge N, Jonigk D, et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis[J]. Sci Rep,2018,8:419. [13] Biewenga M, Heidt S, Vergunst M, et al. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis[J]. JHEP Rep, 2022,4:100460. [14] Lim TY, Martinez-Llordella M, Kodela E, et al. Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis[J]. Hepatology,2018,68:1649-1652. [15] van den Beukel MD, Stoelinga AEC, van der Meer AJ, et al. Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment[J]. Front Med (Lausanne),2023,10:1195747. [16] Wang Q, Selmi C, Zhou X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis[J]. J Autoimmun,2013,41:140-145. [17] Mercado LA, Gil-Lopez F, Chirila RM, et al. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview[J]. Diagnostics (Basel),2024,14. [18] Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice[J]. Clin Rev Allergy Immunol,2022,63:124-137. [19] Wang QX, Jiang WJ, Miao Q, et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: a single center experience[J]. J Dig Dis,2013,14:175-180. [20] Wong LL, Fisher HF, Stocken DD, et al. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility[J]. Hepatology,2018,68:1487-1497. [21] Liberal R, de Boer YS, Andrade RJ, et al. Expert clinical management of autoimmune hepatitis in the real world[J]. Aliment Pharmacol Ther, 2017,45:723-732. [22] Liu P, Li M, Zhao L, et al. Impact of hepatic steatosis on treatment response of autoimmune hepatitis: A retrospective multicentre analysis[J]. Front Immunol, 2022,13:1040029. [23] Tsuneyama K, Baba H, Kikuchi K, et al. Autoimmune features in metabolic liver disease: a single-center experience and review of the literature[J]. Clin Rev Allergy Immunol,2013,45:143-148. |